Baxter International Inc (BAX): John D Forsyth , director of Baxter International Inc sold 1,887 shares on May 2, 2016. The Insider selling transaction was reported by the company on May 4, 2016 to the Securities and Exchange Commission. The shares were sold at $44.38 per share for a total value of $83,745.06 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on Apr 6, 2016, John D Forsyth (director) sold 1,887 shares at $41.75 per share price.On Mar 15, 2016, Albert P L Stroucken (director) sold 5,660 shares at $40.33 per share price.Also, On Mar 15, 2016, James R Iii Gavin (director) sold 5,660 shares at $40.34 per share price.On Feb 19, 2016, Peter S Hellman (director) sold 5,660 shares at $38.35 per share price.
Baxter International Inc: On Wednesday, May 4, 2016 heightened volatility was witnessed in Baxter International Inc which led to swings in the share price. The shares opened for trading at $44.27 and hit $45.25 on the upside , eventually ending the session at $45.12, with a gain of 1.64% or 0.73 points. The heightened volatility saw the trading volume jump to 1,59,93,092 shares. The 52-week high of the share price is $45.25 and the company has a market cap of $24,720 M . The 52-week low of the share price is at $32.18.
Company has been under the radar of several Street Analysts.Baxter International Inc is Reiterated by RBC Capital Mkts to Sector Perform and the brokerage firm has raised the Price Target to $ 47 from a previous price target of $40 .The Rating was issued on Apr 27, 2016.Baxter International Inc is Upgraded by Piper Jaffray to Overweight. Earlier the firm had a rating of Neutral on the company shares. The Rating was issued on Apr 14, 2016.
Baxter International Inc. (Baxter) is a diversified healthcare company. The Company operates in two segments: BioScience segment which include three commercial franchises: Hemophilia BioTherapeutics and BioSurgery and Medical Products segment which include four commercial franchises: Fluid Systems Renal Specialty Pharmaceuticals and BioPharma Solutions. Its BioScience processes recombinant and plasma-based proteins to treat hemophilia and other bleeding disorders; plasma-based therapies to treat immune deficiencies alpha-1 antitrypsin deficiency burns and shock and other chronic and acute blood-related conditions and biosurgery products. Its Medical Products manufactures intravenous (IV) solutions and administration sets premixed drugs and drug-reconstitution systems pre-filled vials and syringes for injectable drugs IV nutrition products infusion pumps and inhalation anesthetics. Its products are used in hospitals kidney dialysis centers and nursing homes among others.